Eledon Pharmaceuticals (ELDN) Price & Analysis

Compare

916 Followers

ELDN Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.32 - $5.54

Previous CloseN/A

Volume121.23K

Average Volume (3M)734.17K

Market Cap

$144.91M

Enterprise Value$158.02M

Total Cash (Recent Filing)$124.88M

Total Debt (Recent Filing)$880.00K

Price to Earnings (P/E)―

Beta0.48

Next Earnings

Nov 06, 2025

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.13

Shares Outstanding59,881,775

10 Day Avg. Volume888,169

30 Day Avg. Volume734,174

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap1.09

Enterprise Value/Revenue823.02

Enterprise Value/Gross Profit1.66K

Enterprise Value/Ebitda-2.04

Forecast

1Y Price Target

$9.00

Price Target Upside264.37% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering7

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessThe KOL was encouraged by the Phase Ib update with tegoprubart and believes that BESTOW has a relatively high probability of success.

Market PotentialWith adequate market support, tegoprubart is expected to treat a meaningful portion of kidney transplant recipients in the de novo setting.

Bears Say

Study DiscontinuationsSix patients discontinued the study due to rejection, patient decision, polyomavirus viremia, and post-transplant hemorrhage.

Eledon Pharmaceuticals News

Eledon Pharmaceuticals’ Tegoprubart: A Promising Buy Rating Amid Unmet Needs in Kidney Transplantation

Analyst Rami Katkhuda of LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals, retaining the price target of...

23d ago

ELDN

Eledon Pharmaceuticals: Promising Developments and Strong Financial Outlook Justify Buy Rating

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Eledon Pharmaceuticals today and set a price target...

25d ago

ELDN

Eledon Pharmaceuticals Advances in Transplant Trials

Eledon Pharmaceuticals, Inc. ( ($ELDN) ) has released its Q2 earnings. Here is a breakdown of the information...

1M ago

ELDN

Buy Rating for Eledon Pharmaceuticals: Promising Kidney Transplant Treatment and Strong Financial Position

Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Eledon Pharmaceuticals and keeping the price target...

1M ago

ELDN

Eledon Pharmaceuticals reports Q2 EPS (13c), consensus (23c)

“We are proud to enter the second half of the year with strong momentum as we have achieved...

1M ago

ELDN

Positive Outlook for Eledon Pharmaceuticals Driven by Promising Tegoprubart Phase 1b Study Results

Eledon Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas Smith from...

2M ago

ELDN

Promising Phase 1b Results of Tegoprubart Support Buy Rating for Eledon Pharmaceuticals

Yi Chen, an analyst from H.C. Wainwright, reiterated the Buy rating on Eledon Pharmaceuticals. The associated price target...

2M ago

ELDN

Eledon Pharmaceuticals announces updated data from tegoprubart trial

Eledon Pharmaceuticals (ELDN) announced updated data from the company’s ongoing open-label Phase 1b trial evaluating tegoprubart for the...

2M ago

ELDN

Eledon Pharmaceuticals Reports Promising Phase 1b Trial Results

Eledon Pharmaceuticals ( ($ELDN) ) has issued an update. On August 6, 2025, Eledon Pharmaceuticals announced updated data...

2M ago

ELDN

Craig-Hallum bullish on Eledon Pharmaceuticals, initiates with a Buy

As previously reported, Craig-Hallum initiated coverage of Eledon Pharmaceuticals (ELDN) with a Buy rating and $12 price target...

2M ago

ELDN

Eledon Pharmaceuticals initiated with a Buy at Craig-Hallum

Craig-Hallum initiated coverage of Eledon Pharmaceuticals (ELDN) with a Buy rating and $12 price target Published first on...

2M ago

ELDN

Eledon Pharmaceuticals Advances Kidney Transplant Study with Tegoprubart

Eledon Pharmaceuticals, Inc. (($ELDN)) announced an update on their ongoing clinical study. Eledon Pharmaceuticals, Inc. is conducting a...

2M ago

ELDN

Eledon Pharmaceuticals: Promising Advances in Organ Transplant Rejection Prevention with Tegoprubart

Leerink Partners analyst Thomas Smith has maintained their bullish stance on ELDN stock, giving a Buy rating on...

2M ago

ELDN

Eledon Pharmaceuticals’ Tegoprubart: Promising Clinical Potential in Kidney Transplantation and Strategic Targeting Advantages

LifeSci Capital analyst Rami Katkhuda has maintained their bullish stance on ELDN stock, giving a Buy rating on...

3M ago

ELDN

ELDN FAQ

What was Eledon Pharmaceuticals’s price range in the past 12 months?

Eledon Pharmaceuticals lowest stock price was $2.31 and its highest was $5.54 in the past 12 months.

What is Eledon Pharmaceuticals’s market cap?

Eledon Pharmaceuticals’s market cap is $144.91M.

When is Eledon Pharmaceuticals’s upcoming earnings report date?

Eledon Pharmaceuticals’s upcoming earnings report date is Nov 06, 2025 which is in 40 days.

How were Eledon Pharmaceuticals’s earnings last quarter?

Eledon Pharmaceuticals released its earnings results on Aug 14, 2025. The company reported -$0.13 earnings per share for the quarter, beating the consensus estimate of -$0.23 by $0.1.

Is Eledon Pharmaceuticals overvalued?

According to Wall Street analysts Eledon Pharmaceuticals’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Eledon Pharmaceuticals pay dividends?

Eledon Pharmaceuticals does not currently pay dividends.

What is Eledon Pharmaceuticals’s EPS estimate?

Eledon Pharmaceuticals’s EPS estimate is -0.24.

How many shares outstanding does Eledon Pharmaceuticals have?

Eledon Pharmaceuticals has 59,881,775 shares outstanding.

What happened to Eledon Pharmaceuticals’s price movement after its last earnings report?

Eledon Pharmaceuticals reported an EPS of -$0.13 in its last earnings report, beating expectations of -$0.23. Following the earnings report the stock price went up 1.154%.

Which hedge fund is a major shareholder of Eledon Pharmaceuticals?

Currently, no hedge funds are holding shares in ELDN

Eledon Pharmaceuticals Stock Smart Score

Neutral

Fundamentals

Return on Equity

-16.20%

Trailing 12-Months

Asset Growth

20.27%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Eledon Pharmaceuticals

Eledon Pharmaceuticals, Inc., clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.

Eledon Pharmaceuticals (ELDN) Earnings & Revenues

Historic Earnings Reports

ELDN Stock 12 Month Forecast

Average Price Target

$9.00

▲(264.37% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","6":"$6","11":"$11","3.5":"$3.5","8.5":"$8.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":9,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$9.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,3.5,6,8.5,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.55,3.1230769230769226,3.696153846153846,4.269230769230769,4.842307692307692,5.415384615384615,5.988461538461538,6.561538461538461,7.134615384615384,7.707692307692307,8.28076923076923,8.853846153846153,9.426923076923076,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.55,3.046153846153846,3.542307692307692,4.038461538461538,4.5346153846153845,5.030769230769231,5.526923076923077,6.023076923076923,6.519230769230769,7.015384615384615,7.5115384615384615,8.007692307692308,8.503846153846155,{"y":9,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.55,2.969230769230769,3.3884615384615384,3.8076923076923075,4.226923076923077,4.646153846153846,5.065384615384615,5.484615384615385,5.903846153846153,6.323076923076923,6.742307692307692,7.161538461538462,7.5807692307692305,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.81,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.3,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.52,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.15,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.22,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.28,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.06,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.79,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.38,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.55,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >